Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 253

1.
3.

Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.

Su XY, Li GD, Liu WP, Xie B, Jiang YH.

Diagn Cytopathol. 2011 Dec;39(12):900-8. doi: 10.1002/dc.21489. Epub 2010 Sep 10.

PMID:
20836004
4.

Markers for metastatic adenocarcinoma in serous effusion specimens.

Shield PW, Callan JJ, Devine PL.

Diagn Cytopathol. 1994;11(3):237-45.

PMID:
7532566
6.

Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers.

Davidson B, Risberg B, Kristensen G, Kvalheim G, Emilsen E, Bjåmer A, Berner A.

Virchows Arch. 1999 Jul;435(1):43-9.

PMID:
10431845
7.

Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions.

Chhieng DC, Yee H, Schaefer D, Cangiarella JF, Jagirdar J, Chiriboga LA, Jagirdar J, Chiriboga LA, Cohen JM.

Cancer. 2000 Jun 25;90(3):194-200.

PMID:
10896333
8.

Immunocytochemical panel for distinguishing between adenocarcinomas and reactive mesothelial cells in effusion cell blocks.

Kim JH, Kim GE, Choi YD, Lee JS, Lee JH, Nam JH, Choi C.

Diagn Cytopathol. 2009 Apr;37(4):258-61. doi: 10.1002/dc.20986.

PMID:
19217030
9.

Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.

Hanley KZ, Facik MS, Bourne PA, Yang Q, Spaulding BO, Bonfiglio TA, Xu H.

Cancer. 2008 Feb 25;114(1):49-56.

10.

Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids.

Afify A, Zhou H, Howell L, Paulino AF.

Acta Cytol. 2005 Nov-Dec;49(6):621-6.

PMID:
16450901
11.
12.

Moc-31, fibronectin and CEA in the differential diagnosis of malignant effusions: an immunocytochemical study.

Athanassiadou P, Gonidi M, Liossi A, Petrakakou E, Nakopoulou L, Zerva C, Athanassiades P.

Pathol Oncol Res. 2000;6(2):100-3.

14.

Immunocytochemical differentiation of reactive mesothelial cells and adenocarcinoma cells in serous effusions with the use of carcinoembryonic antigen and fibronectin.

Athanassiadou P, Athanassiades P, Lazaris D, Kyrkou K, Petrakakou E, Aravantinos D.

Acta Cytol. 1994 Sep-Oct;38(5):718-22.

PMID:
8091904
16.

The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions.

Shield PW, Koivurinne K.

Cytopathology. 2008 Aug;19(4):218-23. Epub 2007 Oct 4.

PMID:
17916095
17.

Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.

Politi E, Kandaraki C, Apostolopoulou C, Kyritsi T, Koutselini H.

Diagn Cytopathol. 2005 Mar;32(3):151-5.

PMID:
15690338
18.

GLUT1 antibody staining in thin-layer specimens of benign and malignant body cavity effusions.

Mensch LS, Weller L, Simmons-Arnold L, Gibson PC, Leiman G, Beatty B.

Acta Cytol. 2002 Sep-Oct;46(5):813-8.

PMID:
12365212
19.

The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology.

Hyun TS, Barnes M, Tabatabai ZL.

Acta Cytol. 2012;56(5):527-32. doi: 10.1159/000339586. Epub 2012 Sep 27.

PMID:
23075894
20.

Use of E-cadherin and CD44 aids in the differentiation between reactive mesothelial cells and carcinoma cells in pelvic washings.

Chhieng DC, Yee H, Cangiarella JF, Symmans WF, Cohen JM.

Cancer. 2000 Oct 25;90(5):299-306.

PMID:
11038427
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk